lobbying_activities: 1445165

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id	filing_uuid	filing_type	registrant_name	registrant_id	client_name	filing_year	filing_period	issue_code	specific_issues	government_entities	income_amount	expense_amount	is_no_activity	is_termination	received_date
1445165	3b3d64e7-7e64-40cc-afcd-e78794345f22	Q3	KNIGHT CAPITOL CONSULTANTS	40036301	GENZYME CORPORATION	2013	third_quarter	HCR	Implementation of, and possible change/repeal to provisions related to the Patient Protection and Affordable Care Act (PL 111-178) and the Reconciliation Act (PL 111-152), including implementation of biosimilars provisions and the Independent Payment Advisory Board. General issues related to reimbursement for pharmaceuticals, including drug pricing, orphan drugs, reimbursement for pharmaceuticals under Medicare Parts B and D, and 340B clinics.	HOUSE OF REPRESENTATIVES,SENATE	40000		0	0	2013-10-16T19:33:34.300000-04:00